INTERSTITIAL LUNG DISEASES

This study is testing whether an oral medication called anlotinib can slow the progression of scarring in the lungs for people with idiopathic pulmonary fibrosis (IPF) or similar progressive lung diseases. It will compare the drug against a placebo in about 30 participants over 5…

This study is testing whether a new oral medicine called nerandomilast can slow down lung scarring in people whose autoimmune disease has affected their lungs. It involves 400 adults whose lung function has not improved with standard treatments. Participants will take either the …

This study is testing a new type of CT scan that can look at both the lungs and heart at the same time in people with interstitial lung disease (ILD). The goal is to find early signs of heart problems, which are common and serious in ILD but often missed until it's too late. Rese…

This study is testing whether a drug called nerandomilast can prevent or slow down lung scarring in people who are at high risk because they have a family history of pulmonary fibrosis and early signs of lung changes on a scan. Participants, who are 40 or older, will take either …

This 10-year French study aims to better understand rare, progressive lung scarring diseases by tracking 3,000 patients and their family members over time. Researchers will collect detailed health information through regular check-ups, scans, and questionnaires to identify patter…

This study aims to better understand the signals seen on lung ultrasound scans in people with chronic lung diseases like COPD and interstitial lung disease. Researchers will collect ultrasound images and breathing data from 25 hospitalized and outpatient participants to learn how…